[go: up one dir, main page]

WO2001008682A3 - Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats - Google Patents

Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats Download PDF

Info

Publication number
WO2001008682A3
WO2001008682A3 PCT/EP2000/007356 EP0007356W WO0108682A3 WO 2001008682 A3 WO2001008682 A3 WO 2001008682A3 EP 0007356 W EP0007356 W EP 0007356W WO 0108682 A3 WO0108682 A3 WO 0108682A3
Authority
WO
WIPO (PCT)
Prior art keywords
flupirtine
cats
dogs
joint diseases
degenerative joint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007356
Other languages
German (de)
English (en)
Other versions
WO2001008682A2 (fr
Inventor
Gabriele Endler
Holger Lehmann
Michael Lobisch
Istvan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Teva GmbH
Original Assignee
Bayer AG
AWD Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL14766700A priority Critical patent/IL147667A0/xx
Priority to BR0012942-9A priority patent/BR0012942A/pt
Priority to AU72717/00A priority patent/AU7271700A/en
Priority to KR1020027001445A priority patent/KR20020040767A/ko
Priority to EP00960383A priority patent/EP1242078A2/fr
Priority to MXPA02000997A priority patent/MXPA02000997A/es
Priority to JP2001513412A priority patent/JP2003530308A/ja
Priority to PL00354484A priority patent/PL354484A1/xx
Priority to HU0301296A priority patent/HUP0301296A2/hu
Priority to HR20020192A priority patent/HRP20020192A2/hr
Application filed by Bayer AG, AWD Pharma GmbH and Co KG filed Critical Bayer AG
Priority to SK171-2002A priority patent/SK1712002A3/sk
Publication of WO2001008682A2 publication Critical patent/WO2001008682A2/fr
Priority to NO20020364A priority patent/NO20020364D0/no
Anticipated expiration legal-status Critical
Publication of WO2001008682A3 publication Critical patent/WO2001008682A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de flupirtine ou de ses sels pharmaceutiques pour traiter les douleurs dues aux maladies dégénératives des articulations chez les chiens et les chats et prévenir leur chronicisation, ces douleurs pouvant s'accompagner d'inflammations.
PCT/EP2000/007356 1999-08-03 2000-07-29 Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats Ceased WO2001008682A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HU0301296A HUP0301296A2 (hu) 1999-08-03 2000-07-29 Flupirtin alkalmazása degeneratív ízületi fájdalom kezelésére
AU72717/00A AU7271700A (en) 1999-08-03 2000-07-29 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
KR1020027001445A KR20020040767A (ko) 1999-08-03 2000-07-29 개와 고양이에서 퇴행성 관절 질환으로 인한 통증을경감시키기 위한 플루피르틴의 용도
EP00960383A EP1242078A2 (fr) 1999-08-03 2000-07-29 Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats
MXPA02000997A MXPA02000997A (es) 1999-08-03 2000-07-29 Uso de flupirtina para aliviar el dolor ocasionado por enfermedades degenerativas de las articulaciones en perros y gatos.
JP2001513412A JP2003530308A (ja) 1999-08-03 2000-07-29 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用
PL00354484A PL354484A1 (pl) 1999-08-03 2000-07-29 Zastosowanie flupirtyny do łagodzenia bólu związanego z chorobami zwyrodnieniowymi stawów u psów i kotów
IL14766700A IL147667A0 (en) 1999-08-03 2000-07-29 Use of flupiritine for alleviating pain caused by degenerative joint diseases in dogs and cats
BR0012942-9A BR0012942A (pt) 1999-08-03 2000-07-29 Aplicação de flupirtin para a diminuição de dores em doenças articulares degenerativas de cães e gatos
HR20020192A HRP20020192A2 (en) 1999-08-03 2000-07-29 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
SK171-2002A SK1712002A3 (en) 1999-08-03 2000-07-29 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
NO20020364A NO20020364D0 (no) 1999-08-03 2002-01-23 Anvendelse av flupirtin for å lindre smerter ved degenerative leddsykdommer hos hunder og katter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14703399P 1999-08-03 1999-08-03
US60/147,033 1999-08-03

Publications (2)

Publication Number Publication Date
WO2001008682A2 WO2001008682A2 (fr) 2001-02-08
WO2001008682A3 true WO2001008682A3 (fr) 2002-07-18

Family

ID=22520069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007356 Ceased WO2001008682A2 (fr) 1999-08-03 2000-07-29 Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats

Country Status (20)

Country Link
EP (1) EP1242078A2 (fr)
JP (1) JP2003530308A (fr)
KR (1) KR20020040767A (fr)
CN (1) CN1399550A (fr)
AR (1) AR025030A1 (fr)
AU (1) AU7271700A (fr)
BR (1) BR0012942A (fr)
CA (1) CA2314746A1 (fr)
CO (1) CO5180569A1 (fr)
CZ (1) CZ2002411A3 (fr)
HR (1) HRP20020192A2 (fr)
HU (1) HUP0301296A2 (fr)
IL (1) IL147667A0 (fr)
MX (1) MXPA02000997A (fr)
NO (1) NO20020364D0 (fr)
PL (1) PL354484A1 (fr)
RU (1) RU2002105502A (fr)
SK (1) SK1712002A3 (fr)
WO (1) WO2001008682A2 (fr)
ZA (1) ZA200200493B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
CA2550023C (fr) 2003-12-16 2011-04-12 Cnsbio Pty Ltd Traitement de la douleur neuropathique
AU2004298288B2 (en) * 2003-12-16 2011-06-30 Relevare Aust. Pty Ltd Methods and compositions
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
EP1789028A2 (fr) * 2004-08-24 2007-05-30 Neuromolecular Pharmaceuticals Inc Compositions pour le traitement de la douleur nociceptive
KR101067443B1 (ko) * 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
ITMI20120896A1 (it) * 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
CN104523634A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种马来酸氟吡汀缓释片及其制备方法
RU2680244C1 (ru) * 2017-12-28 2019-02-19 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинации флупиртина и циклобензаприна для лечения болевых синдромов
CN111371527B (zh) 2018-12-25 2021-08-13 华为技术有限公司 一种数据传输方法及通信设备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189788A1 (fr) * 1985-01-23 1986-08-06 ASTA Pharma Aktiengesellschaft Combinaison synergétique de flupirtine et d'anti-phlogistiques non-stéroidaux
EP0207193A2 (fr) * 1985-06-28 1987-01-07 Degussa Aktiengesellschaft Combinaison synergétique de flupirtine et de 4-acétamido-phénol
EP0467164A2 (fr) * 1990-07-14 1992-01-22 ASTA Medica Aktiengesellschaft Flupirtine en combinaison avec antiparkinsonica pour lutter contre la raideur musculaire
EP0595311A1 (fr) * 1992-10-30 1994-05-04 ASTA Medica Aktiengesellschaft Médicament composé de flupirtin et morphine pour le traitement de douleur et pour éviter une dépendance au morphine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189788A1 (fr) * 1985-01-23 1986-08-06 ASTA Pharma Aktiengesellschaft Combinaison synergétique de flupirtine et d'anti-phlogistiques non-stéroidaux
EP0207193A2 (fr) * 1985-06-28 1987-01-07 Degussa Aktiengesellschaft Combinaison synergétique de flupirtine et de 4-acétamido-phénol
EP0467164A2 (fr) * 1990-07-14 1992-01-22 ASTA Medica Aktiengesellschaft Flupirtine en combinaison avec antiparkinsonica pour lutter contre la raideur musculaire
EP0595311A1 (fr) * 1992-10-30 1994-05-04 ASTA Medica Aktiengesellschaft Médicament composé de flupirtin et morphine pour le traitement de douleur et pour éviter une dépendance au morphine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HERMANN,W.M. ET AL.: "On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis", POSTGRADUATE MEDICAL JOURNAL, vol. 63, no. 3, 1987, pages 87 - 104, XP001037313 *

Also Published As

Publication number Publication date
RU2002105502A (ru) 2004-03-20
WO2001008682A2 (fr) 2001-02-08
IL147667A0 (en) 2002-08-14
PL354484A1 (pl) 2004-01-26
HRP20020192A2 (en) 2004-02-29
AR025030A1 (es) 2002-11-06
CZ2002411A3 (cs) 2003-03-12
CO5180569A1 (es) 2002-07-30
HUP0301296A2 (hu) 2003-08-28
SK1712002A3 (en) 2003-03-04
BR0012942A (pt) 2002-07-09
NO20020364L (no) 2002-01-23
KR20020040767A (ko) 2002-05-30
MXPA02000997A (es) 2003-10-14
NO20020364D0 (no) 2002-01-23
ZA200200493B (en) 2003-04-30
CA2314746A1 (fr) 2001-02-03
CN1399550A (zh) 2003-02-26
JP2003530308A (ja) 2003-10-14
AU7271700A (en) 2001-02-19
EP1242078A2 (fr) 2002-09-25

Similar Documents

Publication Publication Date Title
EP1426375A3 (fr) Dérivés analgétiques de spiroindole
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
HK1041637A1 (zh) Valdecoxib频谱
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
WO2004075832A3 (fr) Methodes et compositions de traitement de douleurs chroniques au moyen de la dhea et de derives de celle-ci
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
WO2001043732A3 (fr) Utilisation d'antagonistes des recepteurs de retinoides dans le traitement de maladies cartilagineuses et osseuses
WO2001008682A3 (fr) Utilisation de flupirtine pour apaiser les douleurs dues aux maladies degeneratives des articulations chez les chiens et les chats
WO2005000331A3 (fr) Methodes et compositions permettant de traiter et de prevenir des troubles degeneratifs des articulations
WO2000021510A3 (fr) Nouvelles formulations de fexofenadine
WO2002100351A3 (fr) Procede de traitement de maladies inflammatoires par administration d'un agoniste ppar-delta
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
SE9603725D0 (sv) New teatment
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
CA2418167A1 (fr) Compositions et procedes permettant de prevenir ou de reduire le risque ou la frequence des blessures du squelette chez les chevaux
WO2000012045A3 (fr) Procede de traitement de troubles neuro-degeneratifs
WO2000048446A3 (fr) Agents therapeutiques
WO2001039792A3 (fr) Utilisation d'inhibiteurs de caspase 9 pour traiter une pathologie oculaire nerveuse
EP1342410A3 (fr) Animaux transgéniques ayant une déficience dans le gène de la galanine
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147667

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000960383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/00493

Country of ref document: ZA

Ref document number: 200200493

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000997

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002/00269

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027001445

Country of ref document: KR

Ref document number: 1712002

Country of ref document: SK

Ref document number: PV2002-411

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 008112657

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 72717/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 517187

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: P20020192A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2002 2002105502

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027001445

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000960383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-411

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000960383

Country of ref document: EP